| (Values in U.S. Thousands) | Sep, 2024 | Jun, 2024 | Sep, 2023 | Jun, 2023 | Mar, 2025 |
| Sales | 0 | 0 | 26,660 | 3,500 | 0 |
| Sales Growth | unch | -100.00% | +661.71% | unch | unch |
| Net Income | -17,470 | -17,840 | 11,280 | -11,280 | 0 |
| Net Income Growth | +2.07% | -258.16% | +200.00% | unch | unch |
Artiva Biotherapeutics Inc (ARTV)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
4.27 +0.23 (+5.69%) 03/21/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 4.27 unch (unch) 16:20 ET
for Fri, Mar 21st, 2025
Artiva Biotherapeutics Inc. is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. The company's lead program includes AlloNK(R). Artiva Biotherapeutics Inc. is based in SAN DIEGO.
Fiscal Year End Date: 12/31